SynthesisBMC cancer2025

Statin use and risk of HCC in patients with MASLD and T2DM: an umbrella review and meta-analysis.

Statin useno clear effectNo clear link with HCC cases.Correlation only, not a test of it.

What moved togetherboth groups pooled, not the treatment’s effect

Correlation · may be no link

−11%−44% to +40%

statin use vs no statin use, in patients with MASLD

Bigger than 2 in 10 on the map

As reported

RR 0.89, 95% CI 0.56–1.40 · the paper's word: HCC incidence

people with liver, in this paper

Already taking statin use, or nottheir own situation, not assigned

on statin use

not on statin use

No clear link with HCC cases−11%

correlation, not a test

the abstract, start to end

… five studies from one meta-analysis (RR: 0.89, 95% CI: [0.56, 1.40]).

← favours treatmentfavours comparator →

could be chance

HCC incidencestatin use vs no statin use, in patients with MASLD

RR 0.890.56–1.40

StatinsLiver & MASLD

1 / 4

2025

2026

this papercites it